New software being used at Englewood Hospital and Medical Center should help detect prostate cancer earlier, eliminate unnecessary testing procedures and help form a treatment plan.
Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease
Anavex Life Sciences recently announced that its clinical trial application for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority.
Photocure Develops a Non-surgical Treatment For HPV
A new non-surgical, tissue-preserving therapeutic procedure is being developed to more effectively remove HPV infection and treat precursors of cervical cancer.
RealBio Technology Transforms Research & Pharmaceutical Testing
RealBio’s technology allows cells grown in a laboratory setting to develop as they would in a normal human body.
Hunting Disease In The Dark: MEDomics Seeks to Treat Mitochondrial Disease Before It Occurs
The core theory behind preventative medicine is almost psychic. To stop a disease from wielding its mighty weapons before it occurs is based on foreknowledge of a patient’s susceptibility to the illness.
ADVENTRX Pharmaceuticals Takes the Next Step In Approval of ANX-530
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they have been successful in sending their ANX-530 (Exelbine) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011.
Oncology Panel Selected in OneMedForum SF 2011
Over 500,000 people will die from cancer in the United States this year. There are many companies developing diagnostics for early detection and advanced therapies to address the various types of cancer.
